Publications by authors named "Robert L Coleman"

100Publications

Asbestos and ovarian cancer: examining the historical evidence.

Int J Gynecol Cancer 2020 Oct 9. Epub 2020 Oct 9.

Gynecologic Oncology, Obstetrics and Gynecology, Arizona Oncology (US Oncology Network), Phoenix, Arizona, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2020-001672DOI Listing
October 2020

Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer.

Int J Gynecol Cancer 2020 Oct 9. Epub 2020 Oct 9.

Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2020-001863DOI Listing
October 2020

Phase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer.

Int J Gynecol Cancer 2020 Oct 5. Epub 2020 Oct 5.

Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2020-001859DOI Listing
October 2020

PARP inhibition as frontline therapy in ovarian cancer.

Clin Adv Hematol Oncol 2020 Sep;18(9):550-556

US Oncology Research, The Woodlands, Texas.

View Article

Download full-text PDF

Source
September 2020

Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.

Gynecol Oncol 2020 Sep 26. Epub 2020 Sep 26.

Stanford University School of Medicine, Stanford, CA, United States; University of California, Los Angeles, CA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.09.017DOI Listing
September 2020

Enhanced immunotherapy with LHRH-R targeted lytic peptide in ovarian cancer.

Mol Cancer Ther 2020 Sep 17. Epub 2020 Sep 17.

Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-20-0030DOI Listing
September 2020

The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers.

Int J Gynecol Cancer 2020 Oct 14;30(10):1608-1618. Epub 2020 Sep 14.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2020-001789DOI Listing
October 2020

Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.

Drugs 2020 Oct;80(15):1525-1535

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas, M.D. Anderson Cancer Center, 1155 Herman Pressler Dr. CPB 6.3279, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-020-01382-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541632PMC
October 2020

Breast cancer (BRCA) gene testing in ovarian cancer.

Chin Clin Oncol 2020 Aug 19. Epub 2020 Aug 19.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; US Oncology Research, The Woodlands, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco-20-4DOI Listing
August 2020

Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study.

Gynecol Oncol 2020 Oct 26;159(1):79-87. Epub 2020 Jul 26.

Arizona Oncology (US Oncology Network), University of Arizona College of Medicine-Phoenix, Creighton University School of Medicine, St. Joseph's Hospital, Phoenix, AZ, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.07.015DOI Listing
October 2020

Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE).

Int J Gynecol Cancer 2020 Sep 20;30(9):1450-1454. Epub 2020 Jul 20.

Department of Women's and Children's Health, Policlinico A Gemelli, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2020-001584DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493891PMC
September 2020

Two viral infections in Japan.

Int J Gynecol Cancer 2020 Aug 16;30(8):1258-1259. Epub 2020 Jul 16.

Gynecology, Universita campus biomedico, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2020-001735DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418619PMC
August 2020

The current status of secondary cytoreduction in ovarian cancer: a systematic review.

Clin Adv Hematol Oncol 2020 Jun;18(6):332-343

University of Cincinnati Medical Center, Cincinnati, Ohio.

View Article

Download full-text PDF

Source
June 2020

NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors.

Mol Cancer Ther 2020 08 4;19(8):1727-1735. Epub 2020 Jun 4.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-19-0977DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415525PMC
August 2020

PARP inhibition in the ovarian cancer patient: Current approvals and future directions.

Pharmacol Ther 2020 09 23;213:107588. Epub 2020 May 23.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pharmthera.2020.107588DOI Listing
September 2020

Improving response to progestin treatment of low-grade endometrial cancer.

Int J Gynecol Cancer 2020 May 6. Epub 2020 May 6.

Queensland Centre for Gynaecological Cancer Research, The University of Queensland, Brisbane, Queensland, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2020-001309DOI Listing
May 2020

A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation.

Support Care Cancer 2020 Apr 27. Epub 2020 Apr 27.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-020-05484-zDOI Listing
April 2020

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.

Cancer Treat Rev 2020 Jun 26;86:102017. Epub 2020 Mar 26.

Aix-Marseille University, Assistance Publique-Hopitaux de Marseille, Centre Hospitalo-Universitaire Timone, Service de Neuro-Oncologie, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2020.102017DOI Listing
June 2020

Innovation abounds in cancer therapy.

Authors:
Robert L Coleman

Int J Gynecol Cancer 2020 04 18;30(4):424-425. Epub 2020 Mar 18.

University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2020-001337DOI Listing
April 2020

Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review.

Int J Gynecol Cancer 2020 05 19;30(5):684-694. Epub 2020 Feb 19.

Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2019-001041DOI Listing
May 2020

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. Reply.

Authors:
Robert L Coleman

N Engl J Med 2020 02;382(7):686

University of Texas M.D. Anderson Cancer Center, Houston, TX

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1916477DOI Listing
February 2020

Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.

Gynecol Oncol 2020 05 7;157(2):386-391. Epub 2020 Feb 7.

Stephenson Cancer Center at the University of Oklahoma HSC, Oklahoma City, OK, USA; Sarah Cannon Research Institute, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.01.042DOI Listing
May 2020

European society of medical oncology (ESMO) 2019 meeting report features practice changing data in gynecologic malignancies.

Gynecol Oncol 2020 02 3;156(2):265-270. Epub 2020 Jan 3.

Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.11.010DOI Listing
February 2020

Corrigendum to "Phase III trials in ovarian cancer: The evolving landscape of front line therapy" [Gynecol. Oncol. 153 (2019) 436-444].

Gynecol Oncol 2020 Feb 16;156(2):512-513. Epub 2019 Dec 16.

Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.12.007DOI Listing
February 2020

Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors.

Int J Gynecol Cancer 2020 01 1;30(1):89-93. Epub 2019 Dec 1.

Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2019-000714DOI Listing
January 2020

Emerging serine-threonine kinase inhibitors for treating ovarian cancer.

Expert Opin Emerg Drugs 2019 12;24(4):239-253

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2019.1696773DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526049PMC
December 2019

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.

N Engl J Med 2019 11;381(20):1929-1939

From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1902626DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941470PMC
November 2019

Clinical and biological significance of expression in endometrial cancer.

Cancer Biol Ther 2020 22;21(2):147-156. Epub 2019 Oct 22.

Departments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384047.2019.1672455DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012102PMC
October 2019

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

N Engl J Med 2019 12 28;381(25):2403-2415. Epub 2019 Sep 28.

From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C.); University of Chicago Medicine (G.F.F.) and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University (D.C.), Chicago, and AbbVie, North Chicago (D.M.S., B.A.B., S.B., C.K.R., P.J.A., M.H.D.) - all in Illinois; NRG Oncology Statistical and Data Center, Roswell Park Cancer Institute, Buffalo (M.F.B.), and Memorial Sloan Kettering Cancer Center, New York (K.B.-M., C.A.) - both in New York; University of Washington-Seattle Cancer Care Alliance, Seattle (E.M.S.); Lillebaelt University Hospital of Southern Denmark, Vejle, and the University of Southern Denmark, Odense (K.D.S.); Prince of Wales Clinical School, University of New South Wales and Royal Hospital for Women (M.F.), and the Northern Cancer Institute (S.B.-H.), Sydney; Jikei University School of Medicine, Tokyo (A. Okamoto), and Aichi Cancer Center Hospital, Nagoya (M.M.) - both in Japan; Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City (K.N.M.); Kaplan Medical Center, Rehovot, Israel (N.E.B.-B.); Huntsman Cancer Institute, University of Utah, Salt Lake City (T.L.W.); Texas Oncology, U.S. Oncology Research Network, Fort Worth (N.G.C.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (A. Oaknin); Women and Infants Hospital, Providence, RI (P.A.D.); Penn Medicine, Philadelphia (M.A.M.); University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea (J.-H.N.); O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham (C.A.L.); Oxford University Hospitals, Oxford, United Kingdom (S.N.); Washington University School of Medicine, St. Louis (A.R.H.); Kaiser Permanente Northern California, San Francisco (R.D.L., M.A.B.); and H.M. Hospitales-Centro Integral Oncológico H.M. Clara Campal, Madrid (J.G.-D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1909707DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941439PMC
December 2019

OVQUEST - Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors.

Gynecol Oncol 2019 10 13;155(1):126-134. Epub 2019 Aug 13.

Prince of Wales Clinical School UNSW, and Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.08.009DOI Listing
October 2019

Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit?

Oncology (Williston Park) 2019 07 16;33(7). Epub 2019 Jul 16.

View Article

Download full-text PDF

Source
July 2019

Joint ENGOT and GOG Foundation requirements for trials with industry partners.

Gynecol Oncol 2019 08;154(2):255-258

GOG-F and Gynecologic Oncology, Ohio State University Wexner Medical Center and JamesCare Gynecologic Oncology at Mill Run, Columbus, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.04.677DOI Listing
August 2019

Joint ENGOT and GOG Foundation requirements for trials with industry partners.

Int J Gynecol Cancer 2019 09 18;29(7):1094-1097. Epub 2019 Jul 18.

GOG-F and Gynecologic Oncology, Ohio State University Wexner Medical Center and JamesCare Gynecologic Oncology at Mill Run, Columbus, Ohio, USA.

View Article

Download full-text PDF

Source
http://ijgc.bmj.com/lookup/doi/10.1136/ijgc-2019-000441
Publisher Site
http://dx.doi.org/10.1136/ijgc-2019-000441DOI Listing
September 2019

Advancing Drug Development in Gynecologic Malignancies.

Clin Cancer Res 2019 08 24;25(16):4874-4880. Epub 2019 May 24.

University of Cincinnati Cancer Institute, Cincinnati, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-0619DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697564PMC
August 2019

Paclitaxel and Alisertib in Recurrent Ovarian Cancer-In Reply.

JAMA Oncol 2019 06;5(6):910-911

Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2019.0562DOI Listing
June 2019

TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy.

J Natl Cancer Inst 2020 01;112(1):38-45

Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djz049DOI Listing
January 2020

Microsatellite instability in endometrial cancer: New purpose for an old test.

Cancer 2019 07 26;125(13):2154-2163. Epub 2019 Mar 26.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32058DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763363PMC
July 2019

Phase III trials in ovarian cancer: The evolving landscape of front line therapy.

Gynecol Oncol 2019 05 12;153(2):436-444. Epub 2019 Feb 12.

Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.02.008DOI Listing
May 2019

Presumed early ovarian cancer with isolated tumor cells in para-aortic sentinel nodes.

Int J Gynecol Cancer 2019 01;29(1):216-220

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://ijgc.bmj.com/lookup/doi/10.1136/ijgc-2018-000005
Publisher Site
http://dx.doi.org/10.1136/ijgc-2018-000005DOI Listing
January 2019

Exploring and comparing adverse events between PARP inhibitors.

Lancet Oncol 2019 01;20(1):e15-e28

Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30786-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292736PMC
January 2019

Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.

Curr Treat Options Oncol 2018 11 15;19(12). Epub 2018 Nov 15.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1155 Herman Pressler Dr. CPB 6.3279, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0572-7DOI Listing
November 2018

A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS).

Gynecol Oncol Rep 2019 Feb 16;27:1-4. Epub 2018 Nov 16.

Department of Gynecologic Oncology and Reproductive Medicine, University of Texas, M.D. Anderson Cancer Center, Houston, TX, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gore.2018.11.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260388PMC
February 2019

Management and Treatment of Recurrent Epithelial Ovarian Cancer.

Hematol Oncol Clin North Am 2018 12;32(6):965-982

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030-1362, USA; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1444, P.O. Box 301402, Houston, TX 77230-1402, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S08898588183075
Publisher Site
http://dx.doi.org/10.1016/j.hoc.2018.07.005DOI Listing
December 2018

Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.

N Engl J Med 2018 Nov 31;379(20):1895-1904. Epub 2018 Oct 31.

From the Department of Gynecologic Oncology and Reproductive Medicine, University of Texas M.D. Anderson Cancer Center, Houston (P.T.R., M.F., R.L.C.); the Department of Gynecologic Oncology, Instituto Nacional de Cancerología, Bogota, and Clínica de Oncología Astorga, Medellin - both in Colombia (R.P.); the Department of Gynecologic Surgery, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (A.L.); the Department of Gynecologic Oncology, Barretos Cancer Hospital, Barretos (M.V.), the Department of Surgical Oncology, Erasto Gaertner Hospital, Curitiba (R.R.), and the Department of Gynecologic Oncology, Albert Einstein Hospital, São Paulo (M.T.) - all in Brazil; the Unit of Gynecologic Oncology Surgery, Department of Obstetrics and Gynecology, San Gerardo Hospital, Monza, Italy (A.B.); the Department of Gynecology, First Affiliated Hospital of Wenzhou Medical University, Wenzhou (X.Y.), the Department of Obstetrics and Gynecology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou (Y.S.), and the Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou (T.Z.) - all in China; the Department of Gynecologic Oncology, Mater Health Services Brisbane, South Brisbane (N.C.), the National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney (K.P.R., V.G., R.A.), and the Queensland Centre for Gynaecological Cancer Research and the Faculty of Medicine, University of Queensland (V.B., A.O.), and the Department of Gynaecologic Oncology, Royal Brisbane and Women's Hospital (J.L.N.), Herston - all in Australia; and the Department of Gynecologic Oncology, Instituto Nacional de Cancerología, Mexico City (D.I.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1806395DOI Listing
November 2018

Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer.

Gynecol Oncol 2018 12 23;151(3):428-432. Epub 2018 Oct 23.

Department of Gynecologic Oncology and Reproductive Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States of America. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258183129
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2018.10.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281799PMC
December 2018

Race and nodal disease status are prognostic factors in patients with stage IVB cervical cancer.

Oncotarget 2018 Aug 17;9(64):32321-32330. Epub 2018 Aug 17.

Department of Gynecologic Oncology and Reproductive Medicine, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.25962DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122357PMC
August 2018

Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma.

Gynecol Oncol Res Pract 2018 18;5. Epub 2018 Aug 18.

Hospital BP Mirante, Martiniano de Carvalho Street, 965, São Paulo, 01323-90 Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40661-018-0063-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098839PMC
August 2018

Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.

Future Oncol 2018 Dec 14;14(30):3101-3110. Epub 2018 Aug 14.

Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0215DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331693PMC
December 2018

Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer.

Obstet Gynecol 2018 09;132(3):545-554

Department of Gynecologic Oncology and Reproductive Sciences and the Department of Biostatistics, the University of Texas MD Anderson Cancer Center, Houston, Texas; and St. Thomas Medical Partners, Gynecologic Oncology, Nashville, and the University of Tennessee Health Sciences Center, Memphis, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/AOG.0000000000002796DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105510PMC
September 2018

When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System.

Int J Gynecol Cancer 2018 10;28(8):1485-1490

The Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000001329DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355335PMC
October 2018

Paclitaxel and Pazopanib in Ovarian Cancer-Reply.

JAMA Oncol 2018 09;4(9):1299

NRG Oncology Statistics & Data Management Center, Roswell Park Cancer Institute, Buffalo, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.1712DOI Listing
September 2018

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.

Ther Adv Med Oncol 2018 22;10:1758835918778483. Epub 2018 Jun 22.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas, MD Anderson Cancer Center, 1155 Herman Pressler Drive, CPB 6.3590, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758835918778483DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024342PMC
June 2018

Metastatic gynecologic malignancies: advances in treatment and management.

Clin Exp Metastasis 2018 08 21;35(5-6):521-533. Epub 2018 Jun 21.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10585-018-9889-7DOI Listing
August 2018

Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach.

JAMA Oncol 2018 11;4(11):1519-1526

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.2761DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248088PMC
November 2018

Clinical trial methodology in rare gynecologic tumor research: Strategies for success.

Gynecol Oncol 2018 06 24;149(3):605-611. Epub 2018 Apr 24.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1155 Herman Pressler Drive, Houston, TX 77030, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.04.008DOI Listing
June 2018

Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis.

Cell Rep 2017 Dec;21(10):2785-2795

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2017.11.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749980PMC
December 2017

A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer.

Gynecol Oncol Res Pract 2017 14;4:16. Epub 2017 Nov 14.

Department of Obstetrics, Gynecology, and Reproductive Sciences, UTHealth McGovern Medical School, 6431 Fannin Street, Rm. 3.152, Houston, TX 77030 USA.

View Article

Download full-text PDF

Source
http://gynoncrp.biomedcentral.com/articles/10.1186/s40661-01
Publisher Site
http://dx.doi.org/10.1186/s40661-017-0053-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684736PMC
November 2017

FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper.

Gynecol Oncol 2017 10 24;147(1):3-10. Epub 2017 Aug 24.

Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2017.08.012DOI Listing
October 2017